Does low-dose prolonged steroid therapy affect the natural history of chronic hepatitis C?

Journal of Medical Virology

Volumn 86, Issue 5, 2014, Pages 758-764

  Romero Gutiérrez, Marta ^a   del Campo Terrón, Santos ^b   Moreno Zamora, Ana ^b   Sánchez Ruano, Juan José ^a   Artaza Varasa, Tomás ^a   Bárcena Marugán, Rafael ^b  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Corticosteroids; HCV viral load; Hepatitis C virus; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; PREDNISONE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE CONTROL STUDY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KNODELL HISTOLOGY ACTIVITY INDEX; LIVER FIBROSIS; LONG TERM CARE; LOW DRUG DOSE; MALE; MEDICAL HISTORY; MIDDLE AGED; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

HEPATITIS C VIRUS;

CORTICOSTEROIDS; HCV VIRAL LOAD; HEPATITIS C VIRUS; LIVER FIBROSIS;

ADULT; AZATHIOPRINE; COHORT STUDIES; ENZYMES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RNA, VIRAL; STEROIDS; TREATMENT OUTCOME;

EID: 84895929980     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23889     Document Type: Article

References (31)

1. Blumberg BS, Alter HJ, Visnich S. 1965. A "New" antigen in leukemia sera. JAMA 191:541-546.
2. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. 1967. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 66:924-931.
3. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. 2006. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 13:297-302.
4. Brok J, Mellerup MT, Krogsgaard K, Gluud C. 2004. Glucocorticosteroids for viral hepatitis C. Cochrane Database Syst Rev CD002904.
5. Castèra L, Forns X, Alberti A. 2008. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48:835-847.
6. Castèra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V. 2010a. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13, 369 examinations. Hepatology 51:828-835.
7. Castèra L, Sebastiani G, Le BB, de Lédinghen V, Couzigou P, Alberti A. 2010b. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 52:191-198.
8. Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, Manns MP, Wedemeyer H, Pietschmann T. 2010. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 138:1875-1884.
9. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. 1983. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85:713-717.
10. Goulding NJ, Guyre PM. 1993. Glucocorticoids, lipocortins and the immune response. Curr Opin Immunol 5:108-113.
11. Goulding NJ. 2004. The molecular complexity of glucocorticoid actions in inflammation-A four-ring circus. Curr Opin Pharmacol 4:629-636.
12. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. 1994. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 107:196-199.
13. Giusti G, Piccinino F, Galanti B, Sagnelli E, Ruggiero G, Gallo C. 1984. Immunosuppressive therapy in chronic active hepatitis (CAH). A multicentric retrospective study on 867 patients. A report from a study group for CAH of the Italian Association for the study of the liver. Hepatogastroenterology 31:24-29.
14. Henry SD, Metselaar HJ, Van DJ, Tilanus HW, Van Der Laan LJ. 2007. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci 1110:439-447.
15. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M. 1989. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364.
16. Lam KC, Lai CL, Trepo C, Wu PC. 1981. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 304:380-386.
17. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Pescador R, Detmer J, Wilber JC, Agliaro L. 1994. Hepatitis C viremia in chronic liver disease: Relationship to interferon-alpha or corticosteroid treatment. Hepatology 19:273-279.
18. Magy N, Cribier B, Schmitt C, Ellero B, Jaeck D, Boudjema K, Wolf P, Labouret N, Doffoel M, Kirn A, Stoll-Keller F. 1999. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 21:253-261.
19. McHutchison JG, Ponnudurai R, Bylund DL, Anguiano A, Pockros PJ, Mondala T, Wilkes LB. 2001. Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: Results of a randomized controlled trial. J Clin Gastroenterol 32:133-137.
20. McHutchison J, Poynard T, Afdhal N. 2006. Fibrosis as an end point for clinical trials in liver disease: A report of the international fibrosis group. Clin Gastroenterol Hepatol 4:1214-1220.
21. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. 1992. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 116:51-53.
22. Poynard T, Bedossa P, Opolon P. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832.
23. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. 2000a. Fibrosis in patients with chronic hepatitis C: Detection and significance. Semin Liver Dis 20:47-55.
24. Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. 2000b. Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol 14:211-228.
25. Rakela J, Redeker AG, Weliky B. 1983. Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis. Gastroenterology 84:956-960.
26. Schalm SW, Summerskill WH, Gitnick GL, Elveback LR. 1976. Contrasting features and responses to treatment of severe chronic active liver disease with and without HBs antigen. Gut 17:781-786.
27. Schiano TD, Te HS, Thomas RM, Hussain H, Bond K, Black M. 2001. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am J Gastroenterol 96:2984-2991.
28. Tage-Jensen U, Schlichting P, Aldershvile J, Andersen P, Dietrichson O, Hardt F, Mathiesen LR, Nielsen JO. 1982. Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification. Liver 2:95-103.
29. Thiele DL, DuCharme L, Cunningham MR, Mimms LT, Cuthbert JA, Lee WM, Combes B. 1996. Steroid therapy of chronic hepatitis: Characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Am J Gastroenterol 91:300-308.
30. Tygstrup N, Andersen PK, Juhl E. 1986. Steroids in chronic B-hepatitis. A randomized, double-blind, multinational trial on the effect of low-dose, long-term treatment on survival. A trial group of the European Association for the Study of the Liver. Liver 6:227-232.
31. Vento S, Di PG, Garofano T, Cosco L, Concia E, Ferraro T, Bassetti D. 1989. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 2:926.